Core Viewpoint - Sichuan Road and Bridge experienced a stock price decline of 2.02% on December 22, with a current price of 9.68 CNY per share and a market capitalization of 84.173 billion CNY. The company has seen a year-to-date stock price increase of 40.88% but has faced a recent decline of 4.35% over the last five trading days [1][2]. Financial Performance - For the period from January to September 2025, Sichuan Road and Bridge reported a revenue of 73.281 billion CNY, reflecting a year-on-year growth of 1.95%. The net profit attributable to shareholders was 5.3 billion CNY, which represents an increase of 11.04% compared to the previous year [2]. - The company has distributed a total of 18.855 billion CNY in dividends since its A-share listing, with 14.054 billion CNY distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Sichuan Road and Bridge reached 60,500, marking a 20.10% increase from the previous period. The average circulating shares per person decreased by 16.59% to 110,993 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 96.117 million shares, a decrease of 18.4692 million shares from the previous period [3].

圆通速递所属申万行业为：交通运输-物流-快递。所属概念板块包括：大盘、MSCI中国、增持回购、 养老金概念、融资融券等。 截至9月30日，圆通速递股东户数3.50万，较上期减少33.33%；人均流通股97683股，较上期增加 48.93%。2025年1月-9月，圆通速递实现营业收入541.56亿元，同比增长9.69%；归母净利润28.77亿元， 同比减少1.83%。 分红方面，圆通速递A股上市后累计派现62.00亿元。近三年，累计派现32.88亿元。 12月19日，圆通速递盘中下跌2.03%，截至11:21，报16.89元/股，成交1.70亿元，换手率0.29%，总市值 578.07亿元。 资金流向方面，主力资金净流出1449.21万元，特大单买入147.15万元，占比0.86%，卖出110.50万元， 占比0.65%；大单买入1627.96万元，占比9.55%，卖出3113.83万元，占比18.28%。 圆通速递今年以来股价涨22.13%，近5个交易日跌4.03%，近20日涨0.48%，近60日跌9.68%。 资料显示，圆通速递股份有限公司位于上海市青浦区华新镇新协路28号，成立日期1992年12月22日， ...

12月19日，华虹公司盘中上涨2.11%，截至10:19，报101.99元/股，成交3.64亿元，换手率0.89%，总市 值1770.55亿元。 华虹公司所属申万行业为：电子-半导体-集成电路制造。所属概念板块包括：上海国资、存储概念、国 资改革、融资融券、大盘等。 截至9月30日，华虹公司股东户数4.90万，较上期增加30.97%；人均流通股0股，较上期增加0.00%。 2025年1月-9月，华虹公司实现营业收入125.83亿元，同比增长19.82%；归母净利润2.51亿元，同比减少 56.52%。 分红方面，华虹公司A股上市后累计派现2.58亿元。 机构持仓方面，截止2025年9月30日，华虹公司十大流通股东中，银河创新混合A（519674）位居第六 大流通股东，持股930.00万股，为新进股东。嘉实上证科创板芯片ETF（588200）位居第七大流通股 东，持股925.89万股，相比上期减少42.77万股。诺安成长混合A（320007）位居第十大流通股东，持股 639.20万股，为新进股东。 责任编辑：小浪快报 资金流向方面，主力资金净流入1242.56万元，特大单买入2175.39万元，占比5.98%， ...

Core Viewpoint - Desay SV Automotive has shown a positive stock performance with a year-to-date increase of 9.48% and a recent 5-day increase of 5.04%, despite a 13.35% decline over the past 60 days [1] Group 1: Financial Performance - As of September 30, 2025, Desay SV reported a revenue of 22.337 billion yuan, representing a year-on-year growth of 17.72% [2] - The net profit attributable to shareholders for the same period was 1.788 billion yuan, reflecting a year-on-year increase of 27.08% [2] - Cumulative cash dividends since the company's A-share listing amount to 2.237 billion yuan, with 1.438 billion yuan distributed over the past three years [3] Group 2: Shareholder and Market Activity - The number of shareholders as of September 30, 2025, was 56,500, a decrease of 4.24% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.43% to 9,789 shares [2] - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.502 million shares to 9.3147 million shares, and Huatai-PB CSI 300 ETF, which decreased its holdings by 238,800 shares to 4.8369 million shares [3] Group 3: Business Overview - Desay SV Automotive, established on July 24, 1986, and listed on December 26, 2017, specializes in the research, design, production, and sales of automotive electronic products [1] - The company's revenue composition includes smart cockpits (64.59%), intelligent driving (28.32%), and connected services and others (7.09%) [1] - Desay SV is categorized under the software development industry, specifically in vertical application software, and is associated with concepts such as Li Auto and Changan Automobile [1]

Core Viewpoint - China Petroleum Capital Co., Ltd. has experienced a decline in stock price and significant net outflow of funds, despite a year-to-date increase in stock price of 33.03% [1] Financial Performance - For the period from January to September 2025, the company reported operating revenue of 25.645 billion yuan, a year-on-year decrease of 12.22%, and a net profit attributable to shareholders of 3.997 billion yuan, down 7.95% year-on-year [2] - The company has cumulatively distributed dividends of 15.115 billion yuan since its A-share listing, with 4.437 billion yuan distributed over the past three years [3] Stock Market Activity - As of December 2, the stock price was 9.01 yuan per share, with a market capitalization of 113.905 billion yuan [1] - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) eight times this year, with the most recent appearance on September 2, where it recorded a net buy of -184 million yuan [1] Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 241,700, while the average circulating shares per person decreased by 13.54% to 52,296 shares [2] - Major shareholders include Hong Kong Central Clearing Limited and various ETFs, with some holdings decreasing compared to the previous period [3]

Core Viewpoint - Yanghe Co., Ltd. has experienced a significant decline in stock price and financial performance, with a notable drop in revenue and net profit for the first nine months of 2025 [2][3]. Financial Performance - As of September 30, 2025, Yanghe Co., Ltd. reported a revenue of 18.09 billion yuan, a year-on-year decrease of 34.26% [2]. - The net profit attributable to shareholders for the same period was 3.98 billion yuan, down 53.66% year-on-year [2]. - The company's stock price has fallen by 18.63% year-to-date, with a 2.31% decline over the last five trading days and a 9.03% drop over the last 20 days [1]. Shareholder Information - The number of shareholders as of September 30, 2025, was 164,100, a decrease of 13.97% from the previous period [2]. - The average number of circulating shares per shareholder increased by 16.24% to 9,180 shares [2]. Dividend Distribution - Since its A-share listing, Yanghe Co., Ltd. has distributed a total of 56.34 billion yuan in dividends, with 19.66 billion yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders included notable entities such as the China Securities Finance Corporation and various ETFs, with changes in their holdings reflecting market dynamics [3].

Core Viewpoint - Northern Rare Earth's stock price has experienced significant fluctuations, with a year-to-date increase of 120.01% and a recent decline in the last 20 and 60 days, indicating volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Northern Rare Earth achieved a revenue of 30.292 billion yuan, representing a year-on-year growth of 40.50%. The net profit attributable to shareholders was 1.541 billion yuan, showing a substantial increase of 280.27% [2]. Stock Market Activity - As of December 2, Northern Rare Earth saw a 2.02% drop in stock price, trading at 46.61 yuan per share with a total market capitalization of 168.498 billion yuan. The stock experienced a net outflow of 62.6501 million yuan in principal funds [1]. - The stock has been on the龙虎榜 (a list of stocks with significant trading activity) twice this year, with the most recent appearance on July 11 [1]. Shareholder Information - As of November 30, the number of shareholders for Northern Rare Earth was 698,900, a decrease of 5.10% from the previous period. The average number of circulating shares per shareholder increased by 5.37% to 5,172 shares [2]. - The company has distributed a total of 5.358 billion yuan in dividends since its A-share listing, with 994 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited, which held 80.357 million shares, a decrease of 58.3304 million shares from the previous period. Other notable shareholders include various ETFs, with some increasing and others decreasing their holdings [3].

Core Viewpoint - Wante Bio's stock has experienced a significant decline this year, with a 30.39% drop, and the company is facing challenges in revenue and profit margins [1][2]. Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09% [2]. - The net profit attributable to the parent company was -173 million yuan, reflecting a year-on-year decrease of 165.04% [2]. Stock Market Activity - As of December 1, Wante Bio's stock price was 49.05 yuan per share, with a market capitalization of 62.054 billion yuan [1]. - The stock has seen a trading volume of 1.06 billion yuan, with a turnover rate of 0.17% [1]. - The stock has experienced a decline of 4.76% over the last five trading days and 11.21% over the last 20 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 42,000, a rise of 9.41% [2]. - The average number of circulating shares per shareholder decreased by 8.60% to 30,124 shares [2]. Dividend Distribution - Wante Bio has distributed a total of 1.541 billion yuan in dividends since its A-share listing, with 1.311 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 12.8991 million shares, a decrease of 9.8553 million shares from the previous period [3]. - The top ten circulating shareholders included new entrants and exits, indicating changes in institutional interest [3].

Core Viewpoint - The stock price of Wens Foodstuff Group Co., Ltd. has shown fluctuations, with a current price of 17.71 CNY per share, reflecting a year-to-date increase of 10.60% but a recent decline over the past 20 and 60 days [1] Financial Performance - For the period from January to September 2025, Wens achieved a revenue of 75.82 billion CNY, representing a year-on-year growth of 0.53%. However, the net profit attributable to shareholders decreased by 17.98% to 5.26 billion CNY [2] - Cumulative cash dividends since the A-share listing amount to 30.11 billion CNY, with 6.28 billion CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.94% to 81,100, while the average circulating shares per person increased by 12.11% to 73,543 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 144 million shares, an increase of 5.50 million shares from the previous period [3]

Core Viewpoint - Wante Bio's stock has experienced a significant decline in 2023, with a year-to-date drop of 31.73% and a recent 60-day decline of 17.40% [2] Company Overview - Wante Bio, established on April 24, 1991, and listed on April 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [2] - The revenue composition of Wante Bio includes: diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active raw materials (0.76%) [2] - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period, with an average of 30,124 circulating shares per shareholder, a decrease of 8.60% [2] Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net profit attributable to shareholders of -173 million yuan, a year-on-year decrease of 165.04% [2] - Since its A-share listing, Wante Bio has distributed a total of 1.541 billion yuan in dividends, with 1.311 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Wante Bio include Hong Kong Central Clearing Limited, which holds 12.8991 million shares (a decrease of 9.8553 million shares), and Huatai-PB CSI 300 ETF, holding 6.4061 million shares (a decrease of 318,300 shares) [3] - The China National Securities Bio-Medical Index A has entered the top ten circulating shareholders with 4.9609 million shares as a new shareholder, while E Fund CSI 300 Medical ETF has exited the list [3] Market Activity - On November 28, Wante Bio's stock price fell by 2.02%, trading at 48.10 yuan per share, with a total transaction volume of 131 million yuan and a turnover rate of 0.21%. The total market capitalization is 60.852 billion yuan [1] - In terms of capital flow, there was a net outflow of 17.3687 million yuan from main funds, with large orders showing a buy of 23.094 million yuan (17.66%) and a sell of 27.222 million yuan (20.82%) [1]